CYTK 250516 25.00C(CYTK250516C25000) Stock Price Today

8.50
-1.20-12.37%

15min DelayClose May 7 16:00 ET

8.50High8.50Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Teddy123

Mar 20 19:46

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

$Cytokinetics (CYTK.US)$
Groundbreaking Healthcare Tool Unlocks Insights from 65,000 Pharmacies' HCM Data

Narga101

Feb 21 07:35

hidden gem right here

$Cytokinetics (CYTK.US)$

Movers and Shakers

Dec 24, 2024 21:57

Columns Today's Pre-Market Movers and Top Ratings | TIVC, NEUE, X, and More

Morning Movers
Gapping up
$Tivic Health Systems (TIVC.US)$ shares jumped 76% in Tuesday premarket after CEO Jennifer Ernst announced plans for 2025 cash flow initiatives and disease-specific clinical trials for regulatory approvals.
$NeueHealth (NEUE.US)$ stock surged 62% after announcing its agreement to be acquired and taken private by a New Enterprise Associates affiliate in a deal valued at approximately $1.3 billion.
$SEALSQ Corp (LAES.US)$ shares c...

Sean Parker

Nov 19, 2024 16:56

$Cytokinetics (CYTK.US)$
Cytokinetics (CYTK) and Bayer have established an exclusive licensing agreement for aficamten in Japan, focusing on treating hypertrophic cardiomyopathy (HCM). The deal includes an upfront payment of €50 million to Cytokinetics, with potential additional earnings of €90 million in milestones through commercial launch (including €20 million near-term) and up to €490 million in commercial milestone payments. The collaboration involves tiered royalties on Japanese sales and ...

Mr Long Term

Aug 14, 2024 06:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...

CYTK250516C25000

News

Comments